PIPAC, or pressurized intraperitoneal aerosol chemotherapy, is showing promising results for mesothelioma, but patients don’t finish all their sessions. This is a problem because the patients then limit the effectiveness of their treatment. Researchers in France decided to figure out why patients are quitting their treatments early. Mesothelioma is a[…]
Overall Survival
Pembrolizumab and Chemotherapy Improve Survival in Pleural Mesothelioma Patients
The mix of chemotherapy and pembrolizumab extended survival in patients with pleural mesothelioma. It was given as a first line treatment to adults with the cancer. Data shows that pembrolizumab and chemotherapy reduced death by 21 percent compared to chemotherapy alone. Doctors like the combination of pembrolizumab and chemotherapy because[…]
Finding Out How Asbestos Causes Mesothelioma
Finding Out How Asbestos Causes Mesothelioma Researchers are finding out why it takes a long time for mesothelioma to develop. A study in the Journal of Environmental Research found that the immune system sensing and interacting with particles changes how mesothelioma develops in the body. Researchers found that the main[…]
Researchers are Trying to Find Ways to Prevent Mesothelioma in Asbestos Exposed Individuals
Researchers are trying to find out if mesothelioma can be prevented. Mesothelioma is a cancer of the lining of certain areas of the body including the lungs, abdomen, heart, and testicles. After asbestos exposure, some people develop mesothelioma over a period of many years. Asbestos fibers become lodged in the[…]
Researchers Tried to Determine Which Second Line Treatment is Best for Mesothelioma
Researchers from China tried to determine whether immunotherapy or chemotherapy is better as a second line treatment option for relapsed pleural mesothelioma. There is no current standard therapy for people whose mesothelioma comes back, which makes it hard for doctors to make treatment decisions for patients. Mesothelioma is very aggressive,[…]
YAP/TEAD Inhibitor is Showing Promising Results for Mesothelioma and NF2-Mutant Cancers
A YAP/TEAD inhibitor is showing promising results for people with mesothelioma and other cancers. The inhibitor, known as VT3989, was well tolerated and had good anti-tumor effects in cancer patients with mesothelioma and NF2 mutations. Results were recently published from the first human study. Seven of 69 patients had radiological[…]
Impact on Survival When People Have a Second Cancer in Addition to Mesothelioma
Researchers decided to look at the relationship between having mesothelioma in addition to a second cancer and their impact on survival. Researchers found that a second cancer did not affect survival for most patients with mesothelioma, but for patients with a specific type of mesothelioma, survival was affected. Mesothelioma is[…]
Cytoreductive Surgery and Chemotherapy Improved for Mesothelioma
Improvements have been made for cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC). This treatment combination is typically performed on people with cancers in the abdominal region. One such cancer is peritoneal mesothelioma. Peritoneal mesothelioma is a cancer of the lining of the abdomen caused by asbestos exposure. Peritoneal mesothelioma is[…]
Accelerated Hypofractionated Radiotherapy for Mesothelioma
A recent study from Italy found that accelerated hypofractionated radiotherapy could be an effective treatment for mesothelioma. This is good news for people suffering from the rare and aggressive cancer. The patients in the study had higher chances of living longer while also having a lower risk of the disease[…]
A Vaccine to Prevent and Treat Mesothelioma Could be Possible in the Future
A vaccine for lung cancer could possibly lead to a vaccine for mesothelioma. The lung cancer immunotherapy drug CIMAvax-EFG is making great progress, and because of this progress, researchers are utilizing the treatment in new ways. The researchers are trying to see how the vaccine can be used to prevent[…]
